MDM2 Cancer Research Results

MDM2, Double Minute 2 homolog: Click to Expand ⟱
Source:
Type: oncoprotein
Oncoprotein MDM2, a major ubiquitin E3 ligase of tumor suppressor p53; overexpression of MDM2 in human cancers is associated with a poor prognosis.
- A gene that encodes a protein involved in the regulation of the p53 tumor suppressor. The p53 protein plays a crucial role in controlling cell cycle progression, DNA repair, and apoptosis (programmed cell death). MDM2 functions primarily as an E3 ubiquitin ligase, which means it tags p53 for degradation, thereby regulating its levels in the cell.
-MDM2 is often overexpressed in various tumors, leading to the inhibition of p53 activity. This can result in uncontrolled cell proliferation, evasion of apoptosis, and increased genomic instability, all of which contribute to tumorigenesis.
Scientific Papers found: Click to Expand⟱
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, EGCG stimulates telomere fragmentation through inhibiting telomerase activity.
DNMTs↓, EGCG reduced DNMTs,
cycD1/CCND1↓, EGCG also reduced the protein expression of cyclin D1, cyclin E, CDK2, CDK4, and CDK6. EGCG also inhibited the activity of CDK2 and CDK4, and caused Rb hypophosphorylation
cycE/CCNE↓,
CDK2↓,
CDK4↓,
CDK6↓,
HATs↓, EGCG can inhibit certain biomedically important molecular targets such as DNMTs, HATs, and HDACs
HDAC↓,
selectivity↑, EGCG has shown higher cytotoxicity in cancer cells than in their normal counterparts.
uPA↓, EGCG blocks urokinase, an enzyme which is essential for cancer growth and metastasis
NF-kB↓, EGCG inhibits NFκB and expression of TNF-α, reduces cancer promotion
TNF-α↓,
*ROS↓, It acts as strong ROS scavenger and antioxidant,
*antiOx↑,
Hif1a↓, ↓ HIF-1α; ↓ VEGF; ↓ VEGFR1;
VEGF↓,
MMP2↓, ↓ MMP-2; ↓ MMP-9; ↓ FAK;
MMP9↓,
FAK↓,
TIMP2↑, TIMP-2; ↑
Mcl-1↓, ↓ Mcl-1; ↓ survivin; ↓ XIAP
survivin↓,
XIAP↓,
PCNA↓, ↓ PCNA; ↑ 16; ↑ p18; ↑ p21; ↑ p27; ↑ pRb; ↑ p53; ↑ mdm2
p16↑,
P21↑,
p27↑,
pRB↑,
P53↑,
MDM2↑,
ROS↑, ↑ ROS; ↑ caspase-3; ↑ caspase-8; ↑ caspase-9; ↑ cytochrome c; ↑ Smac/DIABLO; ↓↑ Bax; Z Bak; ↓ cleaved PPAR;
Casp3↑,
Casp8↑,
Casp9↑,
Cyt‑c↑,
Diablo↑,
BAX⇅,
cl‑PPARα↓,
PDGF↓, ↓ PDGF; ↓ PDGFRb; ↓ EGFR;
EGFR↓,
FOXO↑, activated FOXO transcription factors
AP-1↓, The inhibition of AP-1 activity by EGCG was associated with inhibition of JNK activation but not ERK activation.
JNK↓,
COX2↓, EGCG reduces the activity of COX-2 following interleukin-1A stimulation of human chondrocytes
angioG↓, EGCG inhibits angiogenesis by enhancing FOXO transcriptional activity

4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Urolithin A is better absorbed in the gastrointestinal tract than its parent substances.
Inflam↓, Urolithin A attenuated the pro-inflammatory factors production (IL-6, IL-1β, NOS2 and others) in vitro studies.
IL6↓,
IL1β↓,
NOS2↓,
p53 Wildtype↑, figure 1
MDM2↑,
Snail↓,
E-cadherin↑,
N-cadherin↓,
Vim↓,
NF-kB↓,
mTOR↓, Urolithin A can downregulate several oncogenes such as mTOR and Kirsten-rat sarcoma viral oncogenehomolog (KRAS) and upregulate tumor suppressor genes such as p53
p‑Akt↓, At molecular level urolithin A dose-dependently decreased phosphorylation of AKT
selectivity↑, At the same time, it isimportant to note that urolithin A has minimal impact on normal pancreatic epithelial cells such as humanpancreatic epithelial nestin-expressing cells (HPNE) and HPNE-KRAS
EMT↓, Urolithin A (10 mcM) inhibits epithelial-mesenchymal transition (EMT) in lung cancer cells

4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, exposure to urolithin A decreased cell migratory and invasive capacity
TumCI↓,
EMT↓, urolithin A inhibits lung cancer cell EMT by decreasing Snail protein expression and activity.
Snail↓, urolithin A disrupts the interaction of p53 and mdm2 which leads Snail ubiquitination and degradation.
MDM2↑, Urolithin A Upregulates mdm2 by Inhibiting the Interaction of p53 and mdm2
P53↑, Significantly, urolithin A increased endogenous p53 levels in a dose-dependent manner in p53-wild-type A549 and H460 cells
E-cadherin↑, urolithin A dose-dependently increased epithelial marker E-cadherin and decreased mesenchymal markers N-cadherin and Vimentin.
N-cadherin↓,
Vim↓,


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cl‑PPARα↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   BAX⇅, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Diablo↑, 1,   JNK↓, 1,   Mcl-1↓, 1,   MDM2↑, 3,   p27↑, 1,   survivin↓, 1,   Telomerase↓, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,   pRB↑, 1,  

DNA Damage & Repair ⓘ

DNMTs↓, 1,   p16↑, 1,   P53↑, 2,   p53 Wildtype↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   P21↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   FOXO↑, 1,   HDAC↓, 1,   mTOR↓, 1,  

Migration ⓘ

AP-1↓, 1,   E-cadherin↑, 2,   FAK↓, 1,   MMP2↓, 1,   MMP9↓, 1,   N-cadherin↓, 2,   PDGF↓, 1,   Snail↓, 2,   TIMP2↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   uPA↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 2,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   IL6↓, 1,   NOS2↓, 1,  
Total Targets: 61

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   ROS↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: MDM2, Double Minute 2 homolog
2 Urolithin
1 EGCG (Epigallocatechin Gallate)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:183  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page